Evaluate the Predictive Impact of the MEESSI Score

NCT ID: NCT05340972

Last Updated: 2023-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-15

Study Completion Date

2023-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our primary purpose is to assess MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.

European Society of Cardiology recommend risk stratification for patients with AHF.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Improved risk stratification of acute heart failure (AHF) in the emergency department (ED) may help physicians' decisions regarding patient admission or early discharge disposition. The MEESSI-AHF (Multiple Estimation of risk based on the Emergency department Spanish Score In patients with AHF) score was developed to predict 30-day mortality in patients presenting with AHF EDs in Spain. Whether it performs well in other countries is unknown.

The MEESSI-AHF risk model includes 13 variables readily available on arrival to Emergency Department. The 40% of patients classified as LOW RISK (30-day mortality: \<2%) should be considered as potential candidates to be early discharged from Emergency Department without admission after adequate response to initial treatment. The 10% of patients classified as VERY HIGH RISK (30-day mortality: \>2%) may clearly benefit from hospital admission.

Objective: To externally validate the MEESSI-AHF score in another country.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emergencies Heart Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEESSI score

The score aimed to predict the AHF patient's future in the month following management for ED

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major patient
* Patient admitted to emergencies with final diagnosis of AHF according to the opinion of two emergency experts after consulting the data from the clinical examination, cardiac echocardiography, and BNP level.
* Subject who accept to participate in the research

Exclusion Criteria

* Patient who refuse to participate in the study
* Patient with coronary syndrome with ST segment elevation
* Other causes of dyspnea
* Impossibility of giving the patient informed information
* Pregnant woman
Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Monastir

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pr. Semir Nouira

Pr.Semir Nouira chef of emergency deparment

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Semir Nouira, Pr

Role: PRINCIPAL_INVESTIGATOR

University of Monastir

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Emergency department of University hospital Fattouma Bourguiba

Monastir, , Tunisia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Tunisia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Semir Nouira, Professor

Role: CONTACT

7310600 ext. 216

Khaoula Bel Haj Ali, MD

Role: CONTACT

7310600 ext. 216

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

semir nouira, professor

Role: primary

73106000 ext. 216

Khaoula bel haj ali, MD

Role: backup

29777277 ext. 216

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MEESSI 2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.